Table 2 Multivariate analysis to identify factors predicting inferior outcomes.

From: Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02

 

EFS

OS

HR

95% CI

p

HR

95% CI

p

NCI-HR vs. SR

1.37

1

1.89

0.05

1.53

1.03

2.27

0.03

JACLS risk

1.46

1.1

2

0.02

1.88

1.28

2.77

0.001

ETV6-RUNX1+HHD (absent vs. present)

1.53

1.07

2.2

0.02

1.79

1.11

2.91

0.02

Hypodiploid+other abnormalitiesa (absent vs. present)

0.6

0.44

0.92

0.01

0.59

0.38

0.91

0.02

PPR vs. PGR

1.38

0.84

2.27

0.21

0.93

0.51

1.7

0.82

  1. EFS event-free survival, OS overall survival, HR hazard ratio, CI confidence interval, NCI National Cancer Institute, HR high risk, SR standard risk, PGR prednisolone good response, PPR prednisolone poor response.
  2. aCytogenetic/genetic abnormalities other than ETV6-RUNX1, TCF3-PBX1, high hyperdiploid, 11q23 rearrangement/KMT2A-related fusion, normal karyotype, and karyotypic failure.
Back to article page